Breast cancer
VIKTORIA-2
A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors with or without Gedatolisib as First-Line Treatment in Patients with HR-Positive and HER2-Negative Advanced Breast Cancer (VIKTORIA-2).
Trial overview
Clinical Area
Medical Oncology
Disease
Breast
Disease site
Breast
Study Phase
III
Trial Identifiers
Registration number: NCT06757634
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries